Results for tag: "Pulmonary Alveolar Proteinosis"

Pulmonary Alveolar Proteinosis (PAP) is a rare lung disorder caused by the accumulation of surfactant proteins in the alveoli of the lungs. It is a type of interstitial lung disease, and is characterized by shortness of breath, coughing, and fatigue. Treatment for PAP is typically focused on removing the excess surfactant proteins from the lungs, and can include whole lung lavage, bronchoalveolar lavage, and the use of drugs such as corticosteroids and immunosuppressants. The market for respiratory drugs for PAP is relatively small, but is expected to grow in the coming years due to the increasing prevalence of the disorder. The market is highly competitive, with a number of companies offering treatments for PAP. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis. Show Less Read more